Drug Profile
Esflurbiprofen transdermal - Taisho Pharmaceutical
Alternative Names: Esflurbiprofen plaster; LOQOA Tape; S-Flurbiprofen; SFPP; TT-063Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Tokuhon Corporation
- Developer Taisho Pharmaceutical; Tokuhon Corporation
- Class Analgesics; Antirheumatics; Biphenyl compounds; Fluorobenzenes; Nonsteroidal anti-inflammatories; Propionic acids
- Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inflammation; Pain
- Discontinued Muscle pain; Periarthritis
Most Recent Events
- 22 Feb 2023 No development reported - Phase-III for Pain in Indonesia (Transdermal)
- 22 Feb 2021 Esflurbiprofen transdermal is still in phase III trials for Pain in Indonesia (Transdermal) (NCT03434197)
- 11 Jan 2021 Taisho Pharmaceutical completes a phase III trial in Pain (in patients with knee osteoarthritis) in Indonesia (Transdermal) (NCT03434197)